Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease

Inclusion Criteria:

• The patients (aged 50-85 years) exhibited cognitive decline persisting for over sixmonths;

• Primarily characterized by recent memory impairment and accompanied by reduced dailyliving abilities;

• MMSE scores ranging from 3 to 26;

• MRI findings revealed atrophy in the medial temporal lobe, hippocampus, and cerebralcortex, along with widened sulci and fissures.

Exclusion Criteria:

• Patients were excluded if they had severe visual, hearing, or language impairments;

• Tumors;

• hepatic/renal dysfunction.

• with conditions mimicking AD symptoms-such as normal pressure hydrocephalus,vascular dementia (VD or VaD);

• Parkinson's disease dementia (PDD)-were also excluded;

• patients who had participated in clinical drug trials within the past 30 days orconsumed folate and vitamin B12 at doses exceeding twice the recommended intake wereineligible.